1. International Agency for Research on Cancer. Cervical Cancer: Estimated Incidence, Mortality and Prevalence Worldwide in 2012. Available at: http://globocan.iarc. fr/old/FactSheets/cancers/cervix-new.asp Accessed January/8, 2015. 2. National Advisory Committee on Immunization. Update on Human Papillomavirus (HPV) Vaccines. 2012. 3. Merck Canada Ltd. Gardasil product monograph. July 4 2006. 4. Merck Canada Inc. Gardasil-9 Product Monograph. July 30 2015. 5. GlaxoSmithKline Inc. Cervarix Product Monograph. November 25 2014. 6. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006 Aug 21;24 Suppl 3:S42-51. 7. Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ 2001 Apr 3;164(7):1017-1025. 8. Dickinson JA, Stankiewicz A, Popadiuk C, Pogany L, Onysko J, Miller AB. Reduced cervical cancer incidence and mortality in Canada: national data from 1932 to 2006. BMC Public Health 2012 Nov 16;12:992-2458-12-992. 9. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999 Sep;189(1):12-19. 10. Franco EL, Schlecht NF, Saslow D. The epidemiology of cervical cancer. Cancer J 2003 Sep-Oct;9(5):348-359. 11. Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol 2014 Dec;234(4):431-435. 12. International Agency for Research on Cancer. IARC Monographs - 100B: Human Papillomaviruses. 2012; Available at: Monographs/vol100B/mono100B-11.pdf Accessed January/12, 2015. 13. Canadian Cancer Society’s Advisory Committee on Cancer Statistics, Canadian Cancer Society. Canadian Cancer Statistics 2014. 2014. 14. Mosavi-Jarrahi A, Kliewer EV. Cervical cancer incidence trends in Canada: a 30-year population-based analysis. J Obstet Gynaecol Can 2013 Jul;35(7):620-626. 15. de Sanjose S, Bruni L, Alemany L. HPV in genital cancers (at the exception of cervical cancer) and anal cancers. Presse Med 2014 Oct 30;43(12P2):e423-e428. 16. Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013 Jul 17;8(7):e68329. 17. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)- associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013 Feb 6;105(3):175-201. 18. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011 Nov 10;29(32):4294-4301. 19. Forte T, Niu J, Lockwood GA, Bryant HE. Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992-2009. Cancer Causes Control 2012 Aug;23(8):1343-1348. 20a. Nichols AC, Dhaliwal SS, Palma DA, Basmaji J, Chapeskie C, Dowthwaite S, et al. Does HPV type affect outcome in oropharyngeal cancer? J Otolaryngol Head Neck Surg 2013 Feb 1;42:9-0216-42-9. 20b. Nichols AC, Palma DA, Dhaliwal SS, Tan S, Theuer J, Chow W, et al. The epidemic of human papillomavirus and oropharyngeal cancer in a Canadian population. Curr Oncol 2013 Aug;20(4):212-219. 21. Shack L, Lau HY, Huang L, Doll C, Hao D. Trends in the incidence of human papillomavirus-related noncervical and cervical cancers in Alberta, Canada: a population-based study. CMAJ Open 2014 Jul 22;2(3):E127-32.

ii Contemporary Clinical Questions on HPV-Related Diseases and Vaccination

Made with